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IMPORTANCE We know of no data on the prognostic value of primary tumor location (PTL)
according to BRAF, RAS, and microsatellite instability (MSI) status in patients who have
undergone resection for colon cancer (CC) and have been treated with current standard
adjuvant chemotherapy.
OBJECTIVE To determine the prognostic and predictive value of PTL according to BRAF, RAS,
and MSI status in patients with stage III CC receiving adjuvant treatment with FOLFOX (folinic
acid [leucovorin calcium], fluorouracil, and oxaliplatin) with or without cetuximab.
DESIGN, SETTING, AND PARTICIPANTS This post hoc analysis included patients with available
tumor blocks of resected stage III colon adenocarcinoma who participated in the
Pan-European Trials in Alimentary Tract Cancer (PETACC)-8 phase 3 randomized trial. Among
the 2559 patients who underwent randomization, 1900 were screened by next-generation
sequencing, which showed that 1869 had full information concerning PTL. We categorized
primary tumor site as located proximal (right) or distal (left) to the splenic flexure.
MAIN OUTCOMES AND MEASURES The associations between PTL (right- vs left-sided) and
disease-free survival (DFS), survival after relapse (SAR), and overall survival (OS) were
assessed by Cox models and adjusted for clinical and pathological features, treatment, and
MSI, BRAF, and RAS status.
RESULTS Among the 1869 patients (1056 [57%] male; mean [SD] age, 59.4 [9.5] years) with
full molecular data analyzed, 755 (40%) had a right-sided tumor, 164 (10%) had MSI, 942
(50%) had RAS mutations, and 212 (11%) had BRAF mutations. Right-sided tumor location
was not prognostic for DFS in the whole population but was associated with a shorter SAR
(hazard ratio [HR], 1.54; 95% CI, 1.23-1.93; P = .001) and OS (HR, 1.25; 95% CI, 1.02-1.54;
P = .03). When looking at DFS in the different molecular subgroups, we found similar results
for microsatellite-stable tumors and tumors with MSI; a better DFS in right-sided vs left-sided
tumors in patients with RAS mutations (HR, 0.80; 95% CI, 0.64-1.00; P = .046); and a worse
DFS in right-sided vs left-sided tumors in patients with RAS and BRAF double wild type (HR,
1.39; 95% CI, 1.01-1.92; P = .04). These results were found independently of the treatment
received, and no beneficial effect of cetuximab on DFS or OS was observed in left-sided
tumors.
CONCLUSIONS AND RELEVANCE Although right-sided tumor location is associated with poor
survival in patients with metastatic CC as previously reported, the association with disease
recurrence appears to vary for patients with stage III CC and RAS or BRAF mutations vs those
with double wild type.
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B iological and molecular factors such as microsatelliteinstability (MSI) and KRAS and BRAF mutational sta-tus have recently been proposed as prognostic factors
in nonmetastatic colorectal cancers and may play a role as
stratification factors in future adjuvant trials.1
While the prognostic value of primary tumor location (PTL)
for overall survival (OS) in metastatic colorectal cancer (mCRC)
seems clear and consistent in reports in recent decades, the
prognostic impact of PTL for stage III nonmetastatic colorec-
tal cancer remains unclear. Moreover, as many recent publi-
cations on PTL deal with patients with mCRC treated with anti–
epidermal growth factor receptors, very few data sets report
results in patients with RAS mutations. Finally, greater effec-
tiveness of anti–epidermal growth factor receptors in left-
sided tumors has also been suggested in patients with mCRC.2
We therefore examined the relationship between PTL and
disease-free survival (DFS), OS, and survival after recurrence
(SAR) in patients with stage III colon cancer (CC) who re-
ceived adjuvant FOLFOX (folinic acid [leucovorin calcium],
fluorouracil, and oxaliplatin) alone or combined with cetux-
imab. These data were then assessed according to MSI, RAS,
and BRAF status and treatment received.
Methods
The Pan-European Trials in Alimentary Tract Cancer
(PETACC-8) study was done in accordance with the Declara-
tion of Helsinki (amended 2000) and the International Con-
ference on Harmonization of Technical Requirements of Phar-
maceuticals for Human Use (ICH) Note for Guidance on Good
Clinical Practice and approved by the appropriate ethics com-
mittees. All patients analyzed gave their informed consent for
translational research projects in addition to the informed con-
sent given for the therapeutic trial. Patients with histologi-
cally proven stage III resected colon adenocarcinoma for the
previously reported PETACC-8 trial were randomly assigned
to receive 6 months of FOLFOX or FOLFOX plus cetuximab.3
We categorized PTL as on the right or the left of the splenic
flexure.
Tumor samples were prospectively banked. Methods for
MSI, KRAS, NRAS, and BRAF assessments were previously
described.4,5
The DFS, OS, and SAR curves were estimated with the
Kaplan-Meier method. Differences between groups of pa-
tients were analyzed using log-rank tests and Cox models with
the SAS statistical software package version 9.4 (SAS Insti-




Of 2559 patients who underwent randomization, 1900 were
screened by next-generation sequencing, which showed that
1869 patients had full information concerning PTL (Figure 1).
Of those 1869 patients, 755 (40%) had right-sided tumors, 164
(10%) had MSI, 942 (50%) had RAS mutations, and 212 (11%)
Key Points
Question Is primary tumor location prognostic or predictive,
according to BRAF, RAS, and microsatellite instability status, in
patients with stage III colon cancer receiving adjuvant FOLFOX
(folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) with
or without cetuximab?
Findings In this study of 1869 patients with tumor blocks of
resected stage III colon cancer, for those patients with RAS mutant
or BRAF mutant genotype, disease-free survival was better with
right- vs left-sided tumors; for patients who had RAS and BRAF
double wild type, disease-free survival was worse in those with
right-sided tumors. No predictive effect of sidedness for
cetuximab efficacy was found.
Meaning The association between sidedness and disease
recurrence varied between patients with RAS or BRAF wild type
and those with a mutation; no beneficial effect of cetuximab on
disease-free survival and overall survival in patients with left-sided
tumors was seen in the adjuvant setting.
Figure 1. Flow of Patients in PETACC-8 Trial Molecular Study
755 Patients had right-sided primary tumors
2559 Patients enrolled in PETACC-8
2043 Patients with biological ICF
942 Patients had microsatellite stability
536 Patients had double wild type
515 Patients had RAS mutations
63 Patients had BRAF mutations
33 Patients had microsatellite instability
522 Patients had microsatellite stability
427 Patients had RAS mutations
179 Patients had double wild type
149 Patients had BRAF mutations
131 Patients had microsatellite instability
1869 Had full information about primary
tumor location
1114 Patients had left-sided primary tumors1900 Patients underwent next-generation
sequencing
Of 2559 patients who underwent randomization, 1900 were screened by
next-generation sequencing, which showed that 1869 had full information
concerning PTL. Of those 1869 patients, 755 (40%) had right-sided tumors, 164
(10%) had microsatellite instability, 942 (50%) had RAS mutations, and 212
(11%) had BRAF mutations.
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had BRAF mutations. Demographic and clinical characteris-
tics of the patients in the molecular study (n = 1869) were not
statistically different from those excluded from the molecu-
lar study (n = 690) (eTable 1 in the Supplement). All demo-
graphic and molecular characteristics according to sidedness
are summarized in eTable 2 and eTable 3 in the Supplement.
Outcome in the Whole Population
No difference was noted in DFS when comparing right-sided
with left-sided stage III CC in the whole study population
(Figure 2A). However, SAR (hazard ratio [HR], 1.54; 95% CI, 1.23-
1.93; P = .001) and OS (HR, 1.25; 95% CI, 1.02-1.54; P = .03) were
significantly better for left-sided tumors, and 5-year SAR and
Figure 2. Disease-Free Survival, Overall Survival, and Survival After Recurrence in the Whole Population According to Primary Tumor Location
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3-y Disease-free survival, % (95% CI)
HR (95% CI); P value, log-rank
Adjusted HR (95% CI): P value, Wald
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75.5 (72.5-77.6)
1.00 (0.85; 1.19); P = .98








5-y OS, % (95% CI)
HR (95% CI); P value, log-rank
Adjusted HR (95% CI): P value, Wald
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84.2 (81.8-86.3)
1.25 (1.02; 1.54); P = .03








5-y OS, % (95% CI)
HR (95% CI); P value, Log-rank
Adjusted HR (95% CI): P value, Wald
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31.1 (24.9-37.6)
1.54 (1.23; 1.93); P = .0001














A, No difference was noted in disease-free survival when comparing right-sided with left-sided stage III colon cancer in the whole study population. B, Overall
survival was significantly better for left-sided tumors. C, Survival after recurrence was significantly better for left-sided tumors. HR indicates hazard ratio.
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OS rates were 31.1% vs 18.5% and 84.2% vs 78.6% for left-
sided vs right-sided tumors, respectively (Figure 2B and C).
Multivariable Analysis
In multivariable analysis, the following were associated with
shorter DFS: histopathology grades 3 and 4; TNM categories
pT3, pT4, and pN2; RAS mutations; Eastern Cooperative On-
cology Group Performance Status (ECOG PS) 1 and 2; and bowel
obstruction and/or perforation. Overall survival was also worse
in patients with histopathology grades 3 and 4; TNM catego-
ries pT3, pT4, and pN2; RAS mutations; ECOG PS 1 and 2; and
bowel obstruction and/or perforation. Moreover, patients with
MSI tumors had better OS. Only right-sided, grade 3 or 4, pN2,
and BRAF-mutated tumors were associated with shorter SAR
(eTable 4 in the Supplement).
Outcome in Different Molecular Subgroups
All molecular subgroups’ outcomes are summarized in eTable
5 in the Supplement.
No difference in DFS was reported for right-sided vs left-
sided tumors in microsatellite-stable or MSI tumors (eFigure
1 in the Supplement).
In patients with double wild-type genome, those with
right-sided primary tumors had a shorter DFS compared with
those with left-sided tumors (HR, 1.39; 95% CI, 1.01-1.92;
P = .04), with 3-year DFS rates of 75.7% and 81.9%, respec-
tively (Figure 3A). However, these results were not signifi-
cant (HR, 1.22; 95% CI, 0.86-1.72; P = .26) when adjusted for
histopathological grade, pT, pN, ECOG PS, and bowel obstruc-
tion and/or perforation.
For RAS-mutated tumors, patients with right-sided pri-
mary tumors had a longer DFS compared with those with
left-sided tumors (HR, 0.80; 95% CI, 0.64-1.00; P = .046),
w ith 3-year DFS of 73.4% and 69.6%, respectively
(Figure 3B). These results were still significant (HR, 0.75;
95% CI, 0.59-0.95; P = .02) when adjusted for histopatho-
logical grade, pT, pN, ECOG PS, and bowel obstruction
and/or perforation in a multivariable model. The same
trends were observed when looking at BRAF-mutated
tumors (eTable 5 in the Supplement).
Treatment Outcomes in Right-Sided vs Left-Sided CC
When separately analyzing patients treated with FOLFOX alone
or FOLFOX plus cetuximab, the association of PTL with DFS,
Figure 3. Disease-Free Survival in Patients With RAS and BRAF Double Wild Type and RAS Mutations According to the Primary Tumor Location
0
No. at risk






































RAS and BRAF double wild typeA
0
No. at risk









































3-y, Disease-free survival, % (95% CI)
HR (95% CI); P value, log-rank
Adjusted HR (95% CI): P value, Wald
119
81.9 (78.3-84.9)
1.39 (1.01; 1.92); P = .04
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Adjusted HR (95% CI): P value, Wald
192
69.6 (67.6-71.6)
0.80 (0.64-1.00); P = .046          







A, In patients with RAS and BRAF double wild type, those with right-sided primary tumors had a shorter disease-free survival compared with those with left-sided
tumors. B, For RAS-mutated tumors, patients with right-sided primary tumors had a longer disease-free survival compared with those with left-sided tumors.
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OS, and SAR was comparable to that described in the general
population (eFigure 2 in the Supplement).
In patients with double wild type, there was no statistical
difference in DFS when comparing FOLFOX plus cetuximab vs
FOLFOX alone in both right-sided tumors (HR, 0.89; 95% CI,
0.78-1.26; P = .94) and left-sided tumors (HR, 0.84; 95% CI,
0.59-1.21; P = .34) (eFigure 3 in the Supplement).
Discussion
These data describe the prognostic value of PTL in stage III CC
treated with FOLFOX with full RAS, BRAF, and MSI assess-
ment. We confirmed historical data that right-sided tumors
were older and more likely to be poorly differentiated, ex-
hibit vascular invasion or lymphatic infiltration, and have MSI
and BRAF mutation.6,7 Similarly, at disease relapse, right-
sided tumors had a worse prognosis. This result is similar in
all molecular subgroups presently characterized and is in ac-
cordance with the currently published results of PTL prognos-
tic value in the metastatic setting.2
However, when looking at disease recurrence, patients with
RAS-mutated and/or BRAF-mutated right-sided tumors had a
better DFS than left-sided tumors. Right-sided tumors re-
mained of poor prognosis regarding DFS only in patients with
double wild type.
Some recent studies demonstrated that PTL may be con-
sidered as a predictive factor in RAS wild-type mCRC treated
with chemotherapy and cetuximab.2,8-11 In the present work,
no benefit of adding cetuximab to FOLFOX was observed in
our population of patients with stage III left-sided tumors; nor
was any detrimental effect of adding cetuximab observed in
right-sided tumors.
The major strengths of our study are that patients are com-
ing from a randomized, prospective, registration-designed
phase 3 trial; that all patients were treated with the current stan-
dard FOLFOX chemotherapy regimen (with or without cetux-
imab) in this setting; and that a full RAS and BRAF mutational
profile using next-generation sequencing for all included pa-
tients (not limited to KRAS and BRAFV600E) was deter-
mined together with the MSI assessment.
Limitations
Our work also has limitations. The post hoc design of the pres-
ent analysis and the limited number of patients with BRAF mu-
tations and MSI tumors led to small subgroups for some of the
analyses performed.
Conclusions
Although PTL does not seem to be associated with DFS in the
whole study population, opposite sidedness prognostic val-
ues are observed for RAS and BRAF wild-type and mutant tu-
mors. A larger analysis that uses all currently available adju-
vant trials with complete molecular analysis and takes into
account other prognostic molecular data from the consensus
molecular subtypes12 is needed to confirm these first results
and to better determine the molecular differences explaining
them.
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Hospital Duran i Reynals, Barcelona); Enrique
Aranda Aguilar (Hospital Reina Sofia, Cordoba);
Fernando Rivera Herrero (Hospital Universitario
Marques de Valdecilla, Santander); Josep Tabernero
(coordinator and PI; Hospital. Vall d́Hebron,
Barcelona); Javier Sastre Valera (Hospital Clinico
San Carlos, Madrid); Manuel Valladares Ayerbes
(Complejo Hospitalario Universitario A Coruña, A
Coruña); Jaime Feliu Batlle (Hospital Universitario
La Paz, Madrid); Silvia Gil (Hospital Carlos Haya,
Malaga ; Albert Abad Esteve (ICO Badalona-
Hospital Germans Trias i Pujol, Barcelona); Carlos
Garcia-Giron (Hospital Universitario de Burgos,
Burgos); Guillermo Lopez Vivanco (Hospital de
Cruces, Vizcaya); Antonia Salud Salvia (Hospital
Universitario de Lleida Arnau de Vilanova, Lleida);
Vicente Alonso Orduña (Hospital Miguel Servet,
Zaragoza); Ruth Vera Garcia (Complejo Hospitalario
de Navarra, Pamplona); Javier Gallego (HGU de
Elche, Elche-Alicante); Bartomeu Massuti Sureda
(Hospital General Universitario de Alicante,
Alicante); Jordi Remon (Hospital de Mataro,
Barcelona); Maria Jose Safont Aguilera (Hospital
General Universitario de Valencia, Valencia); Luis
Cirera Nogueras (Hospital Mutua de Terrassa,
Barcelona); Bernado Queralt Merino (Hospital
Universitari de Girona Dr Josep Trueta, Girona);
Cristina Gravalos Castro (Hospital 12 de Octubre,
Madrid); Purificacion Martinez de Prado (Hospital
de Basurto, Bilbao); Carlos Pijaume Pericay
(Consorci Hospitalari Parc Tauli, Barcelona); Manuel
Constenla Figueiras (Hospital Provincial de
Pontevedra, Pontevedra); Inmaculada Guasch
Jordan (Hospital Sant Joan de Deu de Manresa,
Manresa); Maria Jose Gome Reina (Hospital del
Mar, Cadiz); Amelia Lopez-Ladron Garcia (Hospital
El Tomillar-Ntra Sra de Valme, Sevilla); Antonio
Arrivi Garcia-Ramos (Fundacion Hospital Son
Llatzer, Palma Mallorca); Andres Cervantes
(Hospital Clinico Universitario de Valencia,
Valencia); Carlos Fernandez Martos (Instituto
Valenciano de Oncologia, Valencia); Eugenio
Marcuello Gaspar (Hospital de la Santa Creu i Sant
Pau, Barcelona); Ines Cabezas Montero (Hospital
Universitario Sant Joan de Reus, Tarragona); Pilar
Escudero Emperador (Hospital Clinico Universitario
Lozano Blesa, Zaragoza); Ana Leon Carbonero
(Fundacion Jimenez Diaz, Madrid); Manuel Gallen
Castillo (Hospital del Mar, Barcelona); Teresa Garcia
Garcia (Hospital Morales Meseguer, Murcia); Jose
Garcia Lopez (Hospital Universitario Ramón y Cajal,
Madrid); Encarnacion Gonzalez Flores (Hospital
Virgen de las Nieves Ruiz de Alda, Granada); Monica
Guillot Morales (Hospital Son Espases, Palma de
Mallorca); Marta Llanos Muñoz (Hospital
Universitario de Canarias, Santa Cruz de Tenerife);
Ana López Martín (Hospital Severo Ochoa,); Joan
Maurel (Hospital Clinic i Provincial, Barcelona); Juan
Carlos Camara (Fundacion Hospital Alcorcon,
Madrid); Rosario Dueñas Garcia (Hospital Ciudad de
Jaen, Jaen); Mercedes Salgado (Complejo
Hospitalario Ourense, Ourense); Isabel Hernandez
Busquier (Hospital Provincial Castellon, Castellon);
Teresa Checa Ruiz (Instituto de Oncologia
Corachan, Barcelona); Adelaida Lacasta Muñoa
(Hospital. de Donostia, San Sebastian); Miquel
Nogue Aliguer (Hospital General de Vic, Vic); Amalia
Velasco Ortiz de Taranco (Hospital Universitario de
La Princesa, Madrid); Miguel Mendez Ureña
(Hospital General de Mostoles, Mostoles); Ferran
Losa Gaspa (Consorci Sanitari Creu Roja,
Barcelona); Jose Juan Ponce (Hospital Virgen de los
Lirios, Alicante); Carlos Bosch Roig (Hospital
Universitario. Dr. Peset, Valencia); Pedro Valero
Jimenez (Clínica Infanta Luisa, Sevilla); Antonio
Galan Brotons (Hospital Sagunto, Sagunto);
Santiago Albiol Rodriguez (Hospital Espiritu Santo,
Barcelona); Jose Ales Martinez (Hospital Ruber
Internacional de Madrid, Madrid); Liliana Canosa
Ruiz (Hospital Torrecardenas, Almeria); Margarita
Centelles Ruiz (Hospital Sagrat Cor, Barcelona);
United Kingdom; John Bridgewater (coordinator
and PI; North Middlesex University Hospital NHS
Primary Tumor Location and RAS and BRAF Mutations in Colon Cancer Brief Report Research
jamaoncology.com (Reprinted) JAMA Oncology Published online November 22, 2017 E7
© 2017 American Medical Association. All rights reserved.
Downloaded From:  by a University of Chicago Libraries User  on 11/22/2017
Trust, London); Rob Glynne-Jones (Centre for
Cancer Treatment, Mount Vernon Hospital,
Northwood, London); Saad Tahir (Broomfield
Hospital, Chelmsford); Tamas Hickish (Poole
Hospital NHS Trust, Poole and Bournemouth
Hospital, Bournemouth); Jim Cassidy (Beatson
West of Scotland Cancer Centre, Glasgow); Leslie
Samuel (Aberdeen Royal Infirmary, Aberdeen)
Disclaimer: The authors are fully responsible for
the content of this manuscript, and the views and
opinions described in the publication reflect solely
those of the authors.
REFERENCES
1. Taieb J, Le Malicot K, Shi Q, et al. Prognostic
value of BRAF and KRAS mutations in MSI and MSS
stage III colon cancer. J Natl Cancer Inst. 2016;109
(5):djw272.
2. Arnold D, Lueza B, Douillard JY, et al. Prognostic
and predictive value of primary tumour side in
patients with RAS wild-type metastatic colorectal
cancer treated with chemotherapy and EGFR
directed antibodies in six randomized trials. Ann
Oncol. 2017;28(8):1713-1729.
3. Taieb J, Tabernero J, Mini E, et al; PETACC-8
Study Investigators. Oxaliplatin, fluorouracil, and
leucovorin with or without cetuximab in patients
with resected stage III colon cancer (PETACC-8): an
open-label, randomised phase 3 trial. Lancet Oncol.
2014;15(8):862-873.
4. Taieb J, Zaanan A, Le Malicot K, et al. Prognostic
effect of BRAF and KRAS mutations in patients with
stage III colon cancer treated with leucovorin,
fluorouracil, and oxaliplatin with or without
cetuximab: a post hoc analysis of the PETACC-8
trial. [Published online January 14, 2016]. JAMA Oncol.
doi:10.1001/jamaoncol.2015.5225.
5. Taieb J, Balogoun R, Le Malicot K, et al; PETACC8
Investigators. Adjuvant FOLFOX +/- cetuximab in
full RAS and BRAF wildtype stage III colon cancer
patients. Ann Oncol. 2017;28(4):824-830.
6. Benedix F, Kube R, Meyer F, Schmidt U,
Gastinger I, Lippert H; Colon/Rectum Carcinomas
(Primary Tumor) Study Group. Comparison of 17,641
patients with right- and left-sided colon cancer:
differences in epidemiology, perioperative course,
histology, and survival. Dis Colon Rectum. 2010;
53(1):57-64.
7. Jess P, Hansen IO, Gamborg M, Jess T; Danish
Colorectal Cancer Group. A nationwide Danish
cohort study challenging the categorisation into
right-sided and left-sided colon cancer. BMJ Open.
2013;3(5):e002608.
8. Venook AP, Niedzwiecki D, Innocenti F, et al.
Impact of primary (1°) tumor location on overall
survival (OS) and progression-free survival (PFS) in
patients (pts) with metastatic colorectal cancer
(mCRC): analysis of CALGB/SWOG 80405
(Alliance). J Clin Oncol. 2016;34(15)(suppl):3504.
doi:10.1200/JCO.2016.34.15_suppl.3504
9. Heinemann V, Modest DP, von Weikersthal LF,
et al. Gender and tumor location as predictors for
efficacy: influence on endpoints in first-line
treatment with FOLFIRI in combination with
cetuximab or bevacizumab in the AIO KRK 0306
(FIRE3) trial. J Clin Oncol. 2014;32(15)(suppl):
3600.doi:10.1200/JCO.2014.32.15_suppl.3600
10. Douillard JY, Siena S, Cassidy J, et al.
Randomized, phase III trial of panitumumab with
infusional fluorouracil, leucovorin, and oxaliplatin
(FOLFOX4) versus FOLFOX4 alone as first-line
treatment in patients with previously untreated
metastatic colorectal cancer: the PRIME study.
J Clin Oncol. 2010;28(31):4697-4705.
11. Schwartzberg LS, Rivera F, Karthaus M, et al.
PEAK: a randomized, multicenter phase II study of
panitumumab plus modified fluorouracil,
leucovorin, and oxaliplatin (mFOLFOX6) or
bevacizumab plus mFOLFOX6 in patients with
previously untreated, unresectable, wild-type KRAS
exon 2 metastatic colorectal cancer. J Clin Oncol.
2014;32(21):2240-2247.
12. Guinney J, Dienstmann R, Wang X, et al. The
consensus molecular subtypes of colorectal cancer.
Nat Med. 2015;21(11):1350-1356.
Research Brief Report Primary Tumor Location and RAS and BRAF Mutations in Colon Cancer
E8 JAMA Oncology Published online November 22, 2017 (Reprinted) jamaoncology.com
© 2017 American Medical Association. All rights reserved.
Downloaded From:  by a University of Chicago Libraries User  on 11/22/2017
